Form 4: Cardiff Oncology Director Mani Mohindru Reports Stock Option Grant
SEC Form 4 Filing
Director Mani Mohindru reports acquisition of stock options in Cardiff Oncology.
Summary
- Mani Mohindru, a director of Cardiff Oncology, Inc. [CRDF], reported a transaction on June 27, 2024.
- Mohindru acquired 29,700 stock options with an exercise price of $2.33.
- The options become exercisable on June 27, 2025, and expire on June 27, 2034.
- Following the transaction, Mohindru directly owns 128,201 shares of common stock.
Sentiment
Score: 5
Explanation: Neutral sentiment as it's a standard disclosure of stock option grants to a director. It doesn't inherently indicate positive or negative performance.
Positives
- The director's acquisition of stock options could be interpreted as a positive sign, indicating confidence in the company's future performance.
Industry Context
Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. They are closely watched by investors for signals about management's confidence in the company.
Stakeholder Impact
- Shareholders may view the stock option grant as an incentive for the director to work towards increasing shareholder value.
Key Dates
| Date | Description |
|---|---|
| 06/27/2024 | Date of stock options transaction |
| 06/27/2025 | Date stock options become exercisable |
| 06/27/2034 | Expiration date of stock options |
| 07/01/2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.